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Abstract: Hyaluronic acid (HA) has been widely investigated in cancer therapy due to its excellent
characteristics. HA, which is a linear anionic polymer, has biocompatibility, biodegradability,
non-immunogenicity, non-inflammatory, and non-toxicity properties. Various HA nanomedicines
(i.e., micelles, nanogels, and nanoparticles) can be prepared easily using assembly and modification
of its functional groups such as carboxy, hydroxy and N-acetyl groups. Nanometer-sized HA
nanomedicines can selectively deliver drugs or other molecules into tumor sites via their enhanced
permeability and retention (EPR) effect. In addition, HA can interact with overexpressed receptors in
cancer cells such as cluster determinant 44 (CD44) and receptor for HA-mediated motility (RHAMM)
and be degraded by a family of enzymes called hyaluronidase (HAdase) to release drugs or molecules.
By interaction with receptors or degradation by enzymes inside cancer cells, HA nanomedicines allow
enhanced targeting cancer therapy. In this article, recent studies about HA nanomedicines in drug
delivery systems, photothermal therapy, photodynamic therapy, diagnostics (because of the high
biocompatibility), colloidal stability, and cancer targeting are reviewed for strategies using micelles,
nanogels, and inorganic nanoparticles.
Keywords: hyaluronic acid; cancer therapy; drug delivery; micelle; nanogel; silica nanoparticle; gold
nanoparticle; metal organic framework
1. Introduction
In 2018, 609,940 people in the United States died of cancer, one of the leading causes of death [1].
Chemotherapy is widely used to treat many types of cancer, but the low solubility of cancer therapeutics
and the side effects caused by nonselective treatment remain a barrier. To overcome these problems,
targeting nanomedicine is of interest, because it utilizes the anatomical and pathophysiological
abnormalities, leukemic tumor vasculature, and overexpression of specific membrane proteins [2,3].
Hyaluronic acid (HA) is a linear anionic polymer composed of repeating disaccharide units of
β-1,4-D-glucuronic acid-β-1,3-N-acetyl-D-glucosamine. It is a non-sulfated glycosaminoglycan found
throughout the connective, epithelial, and neural tissues [4]. HA contains carboxylic acid, hydroxyl,
and N-acetyl groups, and can easily be combined with other chemicals [5]. It is biocompatible,
biodegradable, non-immunogenic, non-inflammatory, and non-toxic [6], and is widely used for arthritis
treatment, ophthalmic surgery, drug delivery, and tissue engineering. As a drug delivery system, HA
has been conjugated with various chemical drugs, such as paclitaxel (PTX) and doxorubicin (Dox), and
other biopharmaceuticals [6]. The nanosized HA medicine (HA nanomedicine) is selectively transferred
to cancer cells by the enhanced permeability and retention (EPR) effect [7–9]. In addition, selective
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delivery is enhanced by the reaction of HA with a variety of receptors, including cluster determinant
44 (CD44), receptor for HA-mediated motility (RHAMM), and lymphatic vessel endothelial receptor-1
(LYVE-1) [5,6,10]. HA nanomedicines generally have a negative surface charge, which prevents the
clearance by the reticuloendothelial system (RES) [11]. For these reasons, HA nanomedicines have
been extensively studied in the drug delivery field to increase the biocompatibility of the material and
improve the delivery of drugs through passive and active targeting. In this review, we investigate the
types, advantages, and therapeutic applications of HA nanomedicine (Figure 1).
Figure 1. Schematic representation of the advantages and applications of hyaluronic acid (HA). EPR:
Enhanced Permeability and Retention; CD44: Cluster Determinant 44.
2. HA Micelle
Self-assembled polymeric micelles (PMs) have been extensively investigated as targeted drug
carriers given their ability to solubilize water-insoluble anticancer drugs, as well as their excellent
targeting activity to tumors [12–14]. PMs, which are amphiphilic, can encapsulate small hydrophobic
drugs in their hydrophobic core via physical, chemical and electrostatic interaction [15–17], and
can deliver hydrophobic drugs into their destinations [18]. Thus, PMs could improve the efficiency
of anticancer drugs by enhancing drug solubility in water, prolonging blood circulation time, and
selectively accumulating at the tumor via the EPR effect [19–21]. The nanosized (20 ~ 100 nm) structure
of the PMs enables them to preferentially accumulate in angiogenic tumor tissues through the fenestrate
vasculature following systemic administration [19,22]. HA can be conjugated with hydrophobic
polymers, small molecules, and drugs to have high drug-loading efficiency. Additionally, HA can be
coated with positively charged nanocarriers (Figure 2), and can achieve improved antitumor efficacy
via releasing the drugs after specific stimuli, such as redox reactions or exposure to an acidic pH.
2.1. HA Polymeric Micelles (PMs)
Conjugating hydrophobic polymers via grafted polymer [23], block-co-polymers, and ring-opening
polymers [24] with HA has been widely investigated to make amphiphilic polymers which can
self-assemble into micelles [25]. These hydrophobic polymers include diverse hydrophobic units,
such as caprolactone, methacrylate, and ethylene glycol. Park et al. presented a crosslinked
HA PM, composed of polymers grafted to HA, such as HA-b-poly(caprolactone) (HA-b-PCL) and
HA-poly(pyridyl disulfide methacrylate) (HA-b-P(PDSMA)) for in vivo studies [26–28].
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Figure 2. Schematic representation of hyaluronic acid (HA) polymeric micelles. Three possible
sites for modification are shown as green circles. In aqueous solution, amphiphilic HA-ligands can
self-assemble into micelles by encapsulating drugs or conjugating with drugs. Polymers can be grafted
to the HA backbone. Block-co-polymers and small molecules, such as drugs and dendrimers, can
be conjugated with HA. Positively charged molecules or polymers can form micelles with HA via
electrostatic interactions.
In this crosslinking strategy, the disulfide bond was used to conjugate the 2-(pyridyldithio)-ethyl
group on the methacrylate chain, which made a block-co-polymer with HA (Figure 3). Glutathione
(GSH), which can reduce disulfide bonds, is abundant in the cytoplasm of cancer cells. During
its initial circulation, the core-crosslinked HA PM has minimal leakage of the encapsulated drug;
however, the GSH rich tumor-specific environment can trigger a burst release of drugs via cleaving the
crosslinked disulfide bond. These bio-reducible PMs promote the release of drugs in specific stimuli to
improve therapeutic efficacy. To improve selective accumulation at the tumor site, poly(ethylene glycol)
(PEG)-conjugation (PEGylation) was developed [29,30]. The PEGylation provides several advantages,
such as reduction of liver uptake and increased circulation time in the blood, but PEGylation can
disrupt efficient interactions with receptors on the cancer cell [15].
The anticancer drug, camptothecin (CPT), was loaded into PEGylated HA micelles to enhance
anticancer therapy. Hyaluronidase (HAdase) degrades CPT loaded HA nanoparticles (NPs),
CPT-P-HA-NPs, which enables the release of CPT in tumor environment. The Costa group studied
cancer chemo-photothermal therapy (PTT) with HA functionalized micelles loaded with Dox and IR780,
which is a probe that is widely used for phototherapies [31]. Poly(maleic anhydride-alt-1-octadecene)
(PMAO) was grafted onto HA to generate a hydrophobic moiety enabling self-assembly (HPN). This
HA-g-PMAO can be loaded with IR780 and Dox for cancer chemo-phototherapy to make IR-HPN and
IR/Dox-HPN.
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Figure 3. Redox-responsive hydrophobic polymer grafted hyaluronic acid (HA) polymeric micelles.
(A) Chemical structure of HA-poly(pyridyl disulfide methacrylate (HA-b-P(PDSMA)), and (B) schematic
illustration of crosslinked HA polymeric micelles with doxorubicin (Dox). GSH: Glutathione; CC-HAM;
core-crosslinked polymeric micelles based on HA. Reproduced from [27] with permission. Copyright
2015 Elsevier Ltd.
Under near-infrared (NIR) irradiation, IR780 showed high cytotoxicity with PTT. Moreover, Dox
loading provided chemotherapy and induced a synergistic effect in breast cancer cells. Thus, these
strategies demonstrate that polymer grafted HA micelles have high cytotoxicity with drug loading and
provide enhanced antitumor therapy in vitro and in vivo.
2.2. Small Molecules Conjugated to HA Micelles
Instead of grafting hydrophobic polymers, small hydrophobic molecules can be conjugated to the
N-acetyl group and primary hydroxyl group in HA [32]. Many hydrophobic drugs and small molecules
have poor solubility in water. By combining water-soluble HA with these hydrophobic molecules,
drugs can be delivered safely to their destination [33]. First, different amounts of a simple long alkyl
group (hexadodecyl, C16) are conjugated to HA (HAC16), which are then able to self-assemble [34].
HAC16 micelles have been studied for ocular diseases, because they can interact with mucin resulting
in an optimal mucoadhesion. Several lipophilic ophthalmic drugs, specifically corticosteroids, such
as triamcinolone acetonide, triamcinolone, and dexamethasone, are loaded into the HAC16 micelles.
Zhang et al. studied the increasing hydrophobicity of redox-sensitive PMs composed of HA and
deoxycholic acid (DOCA) conjugated via disulfide bonds (HA-ss-DOCA) [9] (Figure 4A). Additionally,
the targeted intracellular drug delivery of PTX loaded into HA-ss-DOCA with high entrapment
efficiency (93.2%) and drug-loading capacities (34.1%) was studied. At high GSH levels, HA-ss-DOCA
was reduced and disassembled to release drugs.
Pharmaceutics 2019, 11, 301 5 of 22
Polymer-drug conjugates (PDCs), which are composed of hydrophobic drugs conjugated with
polymers, have diverse advantages, such as high drug loading and lower pre-drug leakage [35].
Additionally, PDCs are amphiphilic and can self-assemble into micelles. PTX was conjugated to
HA in several ways, such as through disulfide bonds [36], dendrimers [37], and nanocomplexes
(Figure 4) [38,39]. The Huo group presented HA-PTX conjugated micelles with redox-cleavable
disulfide bond (HA-ss-PTX) [36]. The drug loading was over 40%, which is greater than other
loading systems, and the redox sensitive micelles showed burst drug release leading to enhanced
cytotoxicity and higher apoptosis. Additionally, Haag et al. disclosed endosomal pH-responsive
prodrug PTX-conjugated HA dendritic oligoglycerol (HA-dOG-PTX) micelles [37]. With multivalent
drug conjugation of dendrimer, it gives high drug-loading resulting in excellent cytotoxicity to human
breast cancer xenografts. PTX is conjugated to HA through acetal groups, which are cleavable in
endo/lysosomal pH and quickly released from the dendrimer. Thus, by adding hydrophobic small
molecules, such as long alkyl chains and drugs, easy conjugation, amphiphilic properties, and high
drug loading efficiency can be achieved for enhanced targeted anticancer therapy.
Figure 4. Small molecule conjugated hyaluronic acid (HA) micelles (A) Illustration and chemical
structure of bio-reducible HA polymer and deoxycholic acid (DOCA) conjugated via disulfide bonds
(HA-ss-DOCA) encapsulating drugs. Reproduced with permission [9] Copyright 2011 Elsevier Ltd.
(B) PTX-conjugated HA dendritic oligoglycerol (HA-dOG-PTX) via an acetal group linker is responsive
to acidic pH. Reproduced from [37] with permission. Copyright from 2016 Elsevier Ltd.
2.3. HA Coating Micelle
HA is a polyanionic biomacromolecule, which forms electrostatic interactions with positive
nanocarriers. Coating HA on the surface of positive carriers provides active targeting to CD44
receptors and protects the carriers from drug leakage [39]. The Ryu group reported amphiphilic
HA micelles with small molecules, such as mitochondria targeting NIR cyanine and peptide-drug
conjugates, for selective cancer therapy [40,41]. They synthesized mitochondria targeting water-soluble
indocyanine dye (IR-Pyr) with a positively charged pyridinium moiety and formed HA micelles
(HA-IR-Pyr) via electrostatic interactions. The indocyanine dyes are sensitizers of photodynamic
therapy (PDT); thus, the HA-IR-Pyr micelles provide greater anticancer therapy by targeting the
mitochondria of cancer cells with PDT (Figure 5). HA-IR-Pyr showed good tumor accumulation with
the SCC-7 tumor model compared to other PDT dyes indicating that HA is important to targeting tumor.
Positively charged tripeptides (KCK-CPT) conjugated with CPT form nanotube structures in aqueous
solution. The nanostructures are transformed to micelles (HA-KCK-CPT) via electrostatic interaction.
HA-KCK-CPT provided higher selectivity to cancer cells (SCC-7 cells) compared to KCK-CPT. Liu et al.
showed that GSH-responsive prodrug micelles consisted of amphiphilic ferrocenium-tetradecyl
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(Fe-C14), HA, and Dox [42]. In the GSH-rich tumor micro-environment, HA-Fe-C14/Dox micelles were
reduced from hydrophilic ferrocene to hydrophobic ferrocene, resulting in dissociation of micelles and
release of Dox. In vivo experiments showed that HA-Fe-C14/Dox has excellent inhibition of tumor
growth. Wu et al. generated a double layered HA-coated PEI (polyethyleneimine)-g-stearic acid
(PgS) that encapsulated a chiral drug, (−)-gossypol, for cancer therapy [43]. Hydrophobic stearic acid
was grafted to PEI to make amphiphilic branched polymer (PgS). PgS can self-assemble into micelles
in water and encapsulate (−)-gossypol ((−)-G) via electrostatic interaction, i.e., negatively charged
HA covered positive charged PgS micelles. Double layered (−)-G-PgSHAs enhanced the stability of
the chiral drug and the antitumor therapeutic effect in vitro and in vivo. The Luo group developed
HA-coated PMs composed of poly(caprolactone)-b-poly(N,N-diethylaminomethyl methacrylate)-r-poly
(2-(methacryloyloxy)ethyl phosphorylcholine (PCL-PDEAMPC) micelles, which is an amphiphilic
co-polymer [44]. After HA coating, the micelle size slightly increased from 72.6 nm to 76.3 nm. Dox
was loaded into the PCL-PDEAMPC micelle. Micelles themselves are not toxic to cells; however,
Dox-loaded PCL-PDEAMPC-HA micelles are very toxic to 4T1 cells after a 48 h incubation. Therefore,
HA-coated micelles provide several advantages, such as the safe delivery of hydrophobic drugs in
carriers, superior cellular uptake, and antitumor efficacy. Characteristics of HA micelle nanomedicines
are summarized in Table 1, including size and molecular length of HA, etc.
Figure 5. Schematic representation of hyaluronic acid (HA)-coated carriers for cancer therapy
(A) HA-indocyanine dye (IR-Pyr) micelle formation scheme. (B) The importance of HA for
HA-IR-Pyr tumor accumulation; HA-IR-Pyr has better localization compared to IR-Pyr and IR-780 dyes.
Reproduced from [40] with permission. Copyright 2017 The Royal Society of Chemistry.
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Table 1. Characteristics of hyaluronic acid (HA) micelle nanomedicines.
Component Cargo
Drug
loading
Content (%)
Responsive
Stimuli
Therapy
Method
Size
(nm)
Surface
Charge
(mV)
HA MW
(kDa) Ref.
2-(Pyridine-2-
yldisulfanyl)-ethyl
methacrylate
Dox 8 GSH Chemo 148–215 7.4 [27]
Poly(ethylene
glycol) CPTDox 32–34 HAdase Chemo 320 234 [29]
β-Dendritic
oligoglycerol PTX 20.6 pH Chemo 120 −21 9.5 [37]
Deoxycholic acid
(DOCA) PTX 34.1 GSH Chemo 130–300 −31–−37 11 [9]
Hexadecylamine
Dexamethasone,
triamcinolone,
triamcinolone
acetonide
2–6 HAdase Chemo 190–−350 −15–−46 <10 [34]
Ferrocenium
tetradecyl Dox 5.97 GSH Chemo 117 −25.7 100 [42]
Indocyanine dye IR-Pyr HAdase,ROS PDT 30 −40 [40]
Peptide-drug CPT HAdase Chemo 44 −9.4 [41]
Polyethylene-imine
(PEI)
-stearic acid
(−)-Gossypol HAdase Chemo 110.9 −29.6 >100 [43]
DOX: Doxorubicin; PTX: Paclitaxel; CPT: Camptothecin; IR-Pyr: Indocyanine dye; ROS: Reactive Oxygen Species;
Chemo: Chemotherapy; GSH: Glutathione.
2.4. Conclusion of HA Micelles
Micelles are a class of nanocarrier widely used drug delivery systems or cancer therapy. Their
nanometer-sized characteristics can provide effective anticancer therapy through the EPR effect.
There are several advantages in using HA micelles for cancer therapy. Facile conjugation of HA
with hydrophobic drugs or molecules can give amphiphilicity which can assemble into micelles
by encapsulating drugs via chemical conjugation, physical absorption and electrostatic interaction.
Additionally, negatively charged HA easily can cover the positively charged micelles resulting in
enhanced selectivity via avoiding noncontrollable cellular uptake to normal cells and improved
antitumor efficacy via releasing the drugs after specific stimuli, such as redox reactions and an acidic
pH. Thus, HA micelles can become important drug delivery vehicles for targeted cancer cells.
3. HA Nanogels
Nanogels are 3-dimensional hydrogels formed by physical or chemical crosslinking of polymers.
Nanogels have a high affinity to water molecules due to their hydrophilic moieties. Despite that,
nanogels are not dissolved in water but swell, which is a unique property of the nanogel caused
by the crosslinking within polymers. Thus, nanogels have both characteristics of hydrogels and
nanoparticles [45]. In addition, nanogels are attractive nanoplatforms because of many advantages,
such as good biocompatibility, high colloidal stability, high drug loading capacity from large interior
space, and tunable inner network. For these reasons, many types of crosslinking strategies using thiol
groups [46], tetrabutylammonium (TBA) ions [47], cholanic acid [7], or graphenes have been widely
studied to form HA-based nanogels (Figure 6) [48].
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Figure 6. Chemical modification of hyaluronic acid (HA) with (1) functionality groups and
(2) stimuli-responsive moieties. Photo-crosslinking between tetrazole and methacrylate generates a
durable nanogel structure, while disulfide bonds endows degradability to nanogels under reductive
condition (Left). A crosslinker functions as not only the precursor of the nanogel, but also
enzyme-responsive moiety, such as ester group (Middle). To make the nanogels using hydrophilic HA,
a hydrophobic moiety can be post-functionalized on the backbone. (i.e., cholesterol) (Right).
3.1. Methacrylate-Modified HA Nanogels
Methacrylate groups are frequently used to form HA-based nanogels with hydrophobic molecules.
Zhong et al. reported an HA nanogel for targeted protein delivery (Figure 7). The group prepared
the HA nanogels by inverse nanoprecipitation of methacrylate- and tetrazole-conjugated HA and the
subsequent photo-crosslinking under UV light. Two intracellular apoptotic protein drugs, cytochrome
c (CC) and granzyme B (GrB), were loaded into the nanogels. HA nanogels encapsulated the proteins
safely due to photo-crosslinking and released nearly 99% of CC under high concentrations of GSH,
which can degrade disulfide linkers in nanogels. They observed strong fluorescence of tetrazole
in the cytoplasm in confocal laser scanning microscopy (CLSM) images, indicating high cellular
internalization of HA nanogels into MCF-7 cells, which have an abundance of HA-receptors on
their membrane.
Figure 7. Schematic representation of a delivery platform with methacrylate- and tetrazole-modified
hyaluronic acid (HA)-based nanogels for therapeutic proteins and granzyme B. Adapted from [49]
with permission. Copyright (2016) American Chemical Society.
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Inhibition of tumor growth using HA nanogels was also confirmed by an in vivo antitumor
experiment [49]. In other studies by Zhong et al. the introduction of the GE11 peptide (YHWYGYTPQNVI)
on the HA backbone allowed the nanogel to target epidermal growth factor receptor (EGFR); thus, the
nanogel system was able to dual-target EGFR and CD44 over-expressed cells [50].
Jiang et al. reported enzyme-sensitive HA nanogels to target cancer. Methacrylate modified
on HA binds with di(ethylene glycol) diacrylate (DEGDA), which act as a crosslinker between
polymers, forming nanogels. Dox was encapsulated within the nanogel via diffusion into networks.
The group determined that HA nanogels could preferentially internalize CD44-overexpressed 2D
and 3D multicellular spheroids (MCs). The biodegradable ester linkage in the nanogels is cleaved by
lipase and HAdase; thus, Dox molecules encapsulated in the nanogel can be released in the presence
of enzyme. As Dox-loaded nanogels were treated with multiple enzymes (lipase and HAdase) and
exposed to low pH condition, 75% of the encapsulated Dox was released within 120 h, indicating the
degradation of the nanogels. Additionally, HA nanogels showed high penetration and accumulation at
CD44 positive cell lines comparable to cell lines with fewer CD44 receptors [51]. Jiang et al. also used
HA nanogels to selectively treat CD168 overexpressed cancer cells. Methacrylate-modified HA formed
nanogels with the addition of a disulfide containing crosslinker; as a result, the nanogels targeted the
CD168-expressed cell line and released Dox in the presence of GSH in cancer cells [52]. Tang et al.
encapsulated the Dox in the methacrylate-crosslinked HA nanogels for targeted drug delivery. HA was
functionalized with methacrylate group and further crosslinked using a di-methacrylate containing
linker, forming nanogels. Through CD44-mediated endocytosis, loaded Dox was selectively delivered
into the cancer cell [53].
3.2. Cholesterol-HA Nanogels
Cholesterol is a molecule which enables the construction of the cellular membrane. Modifications
with cholesterol on HA not only endows hydrophobicity to HA, forming well-crosslinked nanogels,
but also enhances the permeability of nanogels into the cell [54].
Vinogradov et al. demonstrated that HA-based nanogels conjugated with drugs could deliver
cytotoxic nucleosides selectively to CD44-positive drug-resistant cancer cells (Figure 8). Cholesterol-
modified HA (CHA) has been conjugated with etoposide (ETO), salinomycin (SAL), and curcumin
(CUR) (CHA-ETO, CHA-SAL, and CHA-CUR, respectively). Each drug-conjugated CHA easily
formed a 30 nm-sized nanogel after ultrasonication. Due to their hydrophobic moieties, cholesterol
makes nanogels more compact. To improve the binding efficacy of HA to the CD44 receptor, HA
with molecular weight of 60 kDa was selected so that nanogels with smaller size and high loading
amount could be synthesized. While the UV absorbance of free CUR molecules decreased, CHA-CUR
nanogels showed no significant decrease in absorbance within 24 h, indicating that the drug stability is
greatly enhanced after loading in nanogels. In addition, CHA-drug nanogels had high cytotoxicity
and cellular uptake in well-known drug-resistant human breast carcinoma cells, MDA-MB-231/F, and
in pancreatic adenocarcinoma cells, MIA PaCa-2, compared with free drug molecules and nanogels
without cholesterol [55]. Vinogradov et al. also reported that cholesteryl-HA can deliver CUR
with high cellular permeability and accumulation. These nanogels efficiently killed cancer cells by
inducing apoptosis and simultaneously suppressing the immune response mediators, such as nuclear
factor-kappa B (NF-kB), tumor neurosis factor (TNF)-α, and chitosan oligosaccharides (COS)-2 [56].
Akiyoshi et al. designed cholesterol-containing HA nanogels for therapeutic delivery of the recombinant
human growth hormone (rhGH) protein. In their nanogel system, size or density was controlled by
adjusting the amount of salt, and rhGH was released in sustained manner [57].
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Figure 8. (A) Schematic representation of cholesterol-modified hyaluronic acid (HA) nanogel
formation. (B) Scheme of modification of HA with cholesterol and drug molecules. Reproduced
from [55] with permission. Copyright (2013) American Chemical Society. CHA: Cholesterol
modified HA; DCM: Dichloromethane; EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOBT:
Hydroxy-benzotriazole; DMSO: Dimethylsulfoxide; DCC: N,N’-Dicyclohexylcarbodiimide.
3.3. Acetylated HA Nanogels
The hydrophobic acetyl group is generally used to form HA-based nanogels. Na et al. developed
a low molecular weight acetylated HA for efficient drug delivery to cancer cells (Figure 9). As a
strategy to impart hydrophobicity to HA to form nanogels, acetylation was performed on the HA
backbone first, and Dox-loaded nanogels were prepared through a dialysis method. To investigate
the effect of hydrophobicity on nanogels, different numbers of acetyl groups were modified on the
HA (0.8, 2.1, and 2.6). Hydrophobic interactions, not only within the acetyl groups on the HA, but
also between acetyl group and Dox molecules, reduced the swelling of the nanogels; this resulted
in a nanogel size of less than 300 nm and enhanced loading efficiency (>90%) with higher degree
of acetylation. Additionally, the amount of drug released in 1 day was 38%, 42%, and 67% for
modifications to 0.8, 2.1, and 2.6 acetyl groups, respectively. This suggests that the drugs in the
nanogels were stable. One of the merits of HA-based nanogels is biocompatibility. In a cell viability test,
the survival rate of cells treated with nanogels only was above 90%; however, Dox-loaded nanogels
showed significant cytotoxicity against HeLa cells which was comparable to free Dox molecules [58].
Figure 9. Schematic representation of anticancer drug, Dox, loaded into hyaluronic acid (HA)
nanogels with conjugated acetyl groups. Reproduced from [58] with permission. Copyright 2010 from
Elsevier Ltd.
Na et al. reported an acetylated HA conjugated with a photosensitizer for PDT (Figure 10).
HA was functionalized with acetic anhydride to form nanogels with pheophorbide (Pba), a highly
singlet oxygen generating photosensitizer. Pba-quenching hydrogels can be degraded by enzymes in
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the endosome, and UV light-activated Pbas form singlet oxygen molecules, leading to intracellular
dysfunction. The self-quenching effect due to the acetyl group on HA confirmed that the fluorescence
intensity of pyrene decreased dramatically as the concentration of Ac-HA-Pba increased. Comparing
the fluorescence of Ac-HA-Pba in DMSO and PBS, PBS prevented the interactions between the nanogels
and the Pbas, leading to the self-quenching effect on Pbas. Ac-HA-Pba also showed high cellular
uptake into HeLa cells, which is a CD44-overexpressed cell line, in CLSM images. Using fluorescent
probes (CalceinAM and EthD-1), visible amounts of dead cells were observed by phototoxicity-induced
UV irradiation [59]. In additional studies from Na et al., an acetylated HA-based nanogel was used as
a drug carrier for PDT. Both triggers—light and acidic pH—induced the apoptosis of cancer cells [60].
We summarized characteristics of HA nanogel nanomedicines in Table 2, including size and molecular
length of HA.
Figure 10. (A) Schematic representation of photosensitizer, pheophorbide (Pba), quenchable hyaluronic
acid (HA)-based nanogels and single oxygen generation induced by Pba activation under UV irradiation.
(B) Synthetic scheme of acetylated HA nanogels further conjugated with Pba. Reproduced from [59]
with permission. Copyright (2010) American Chemical Society. DCC: N,N’-Dicyclohexylcarbodiimide;
DMAP: 4-Dimethylaminopyridine.
Table 2. Characteristics of hyaluronic acid (HA) nanogel nanomedicines.
Component Cargo
Drug
Loading
Content (%)
Responsive
Stimuli
Therapy
Method
Size
(nm)
Surface
Charge
(mV)
HA MW
(kDa) Ref.
HA-Cys-methacrylate,
HA-Lys-tetrazole
Cytochrome C,
granzyme B 89.2 GSH
Protein
(Induce
apoptosis)
150 −17.6 35 [49]
Methacrylated HA,
DEGDA Dox 16
Enzyme
(lipase and
HAdase)
Chemo 50 −45.0 7 [51]
Membrano-tropic
cholesteryl-HA,
cholesterol-modified
HA
Etoposide,
salinomycin,
and curcumin
20
Hydrolysis
(ester
linkage)
Chemo 20–40 −31.6–−41.4 62 [55]
Methacrylated HA Dox 24
GSH
(Disulfide
bond)
Chemo 79 −40 0.5 [58]
Cholesteryl-HA Curcumin 20
pH,
proteolytic
enzyme
Chemo 29.2 −38.4 0.58 [59]
Acetic anhydride Dox 93.1 Chemo 275 −31 7 [52]
Acetic anhydride Pheophorbide 0.31 per 1unit of HA Enzyme
Photo-
dynamic 125–150 −21–−34 62 [56]
GSH: Glutathione; Chemo: Chemotherapy; Dox: Doxorubicin.
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3.4. Conclusion of HA Nanogels
Nanogels are hydrogels physically or chemically crosslinked by polymers. While nanogels are
water-friendly due to their hydrophilic moieties, crosslinked polymers make nanogels not fully dissolve
in water. Nanogels can be constructed with various types of materials. Among them, hyaluronic acid is
one of materials that can easily form nanogel simply by conjugating with hydrophobic group, such as
methacrylate group, cholesterol, or acetyl group, et cetera. Further crosslinking within the materials is
a facile method to build final nanogels. Hyaluronic acid is known for its high biocompatibility, so when
it becomes nanogel, high drug-loading nanocarriers even with colloidal stability can be applicable to
safe drug delivery system.
4. HA Inorganic Nanomedicines
Inorganic nanomedicines are attracting much attention due to the unique physicochemical
properties of inorganic moieties. These properties include inertness, stability, and ease of
functionalization [61–63]. HA modifications to inorganic nanoparticles not only increases the cancer
targeting ability of inorganic nanomedicine [64], but also increases the theranostic effect, such as
controlling drug release [65,66], colloidal stability [67], and increasing biocompatibility [68,69], of
the nanomedicine. Inorganic particles that are primarily used in nanomedicine, including silica
nanoparticles (SiNPs), gold nanoparticle (AuNP), and metal organic frameworks (MOF), have been
actively studied in recent years.
4.1. SiNPs
SiNPs have excellent biocompatibility, systemic stability, tunable particle size, and controllable
surface chemistry [70,71]. Mesoporous silica nanoparticles (MSNs), which are used for the delivery of
biomolecules and cancer drugs to cancer cells, have advantages as drug carriers because of their high
surface area and tunable pore size [64]. Hou et al. showed that 5-fluorouracil-loaded HA conjugated
SiNPs (5-FU/HSNP) increased the therapeutic effect of colon cancer in vivo [69]. In order to modify
HA on SiNPs, the surface functional group of the nanoparticle was converted from hydroxy (OH) to
amine (NH2) by aminosilane (3-aminopropyltriethoxysilane (APTES)) (Figure 11). After modification,
HA was conjugated on the surface of SiNPs. The amine functional group of the SiNPs was reacted
with the carboxylic group of HA by an EDC reaction. 5-FU/HSNP prevented the rapid clearance of
5-FU, and thus had a better colon cancer therapeutic effect by inducing the cellular uptake of SiNPs.
Figure 11. Schematic representation of inorganic nanoparticle hyaluronic acid (HA) modification
methods and properties. SiNP: silica nanoparticle; AuNP: gold nanoparticle; MOF: metal organic
frameworks; SPR: Surface plasmon resonance.
Ding et al. used a different method for HA modification to the MSNs (Figure 12A) [72]. This
method utilized electrostatic interactions between the negatively charged HA and positively charged
MSNs which was modified by APTES to endow the positively charge. HA improved cancer cell
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targeting as well as increased cellular uptake, biocompatibility, and colloidal stability (Figure 12B).
HA also triggered the controlled drug release. In a study by Qu et al., HA prevented unexpected
drug release by blocking the silica pore [65]. The blocked pore was opened by HAdase, which
is overexpressed in cancer cells. Thus, HA mediated the controlled drug release at cancer cells
(Figure 12C). Siling et al. inserted the disulfide bond between the HA and silica conjugation for the
dual stimuli responsive system [73,74].
The theranostic application of HA-modified SiNPs or MSNs are determined by the loaded
drug in the nanoparticles. Cancer drugs, such as Dox [64,65], CPT [75], and curcumin, are loaded
for chemotherapy [71], and photosensitizer, such as porphyritic derivates, are loaded for PDT to
nanoparticles [76].
Monduzzi et al. prepared nanoparticles modified with different lengths of HA and compared
their hydrodynamic size, zeta potential, and cellular uptake ability after 24 h. Lengths of each HA were
8–15 kDa (HAS), 30–50 kDa (HAM), and 90–130 kDa (HAL) and all of HA were modified on the surface
of amine-coated SiNP via EDC coupling. Nanoparticle with longer chain of HA showed decrease in
zeta potential. However, HAL-modified SiNP was the smallest in size as 168 ± 11 nm and size of HAS-
and HAM-SiNP were 192 ± 15 nm, and 197 ± 8 nm each. This increasing tendency in size is because
HAL could interact with nanoparticle with multi-point attachment. In cell incubation experiment in
HeLa cells, high cellular uptake was observed for HAS modified SiNP [77]. Characteristics of HA silica
nanomedicines are also summarized in Table 3.
Figure 12. (A) Schematic representation of the preparation of TH287 and siRNA-loaded hyaluronic acid
(HA) assembled mesoporous silica nanoparticles (MSNs). Reproduced with permission [72] Copyright
2018 Elsevier Ltd. (B) Confocal microscopy images of HCT-116 cells without any treatment as a control
(first row), with the treatment fluorescein isothiocyanate (FITC) labelled HA-MSNs (second row),
MSNs (third row), and free HA (10 mg mL−1) combined with FITC labelled HA-MSNs (last row).
Reproduced with permission [64] Copyright 2013 The Royal Society of Chemistry. (C) Responsive
release of rhodamine B from MSNs-HA by the addition of HAdase solution after incubation for 3 h.
Reproduced from [65] with permission. Copyright 2013 John Wiley & Sons, Inc.
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Table 3. Characteristics of hyaluronic acid (HA) silica nanomedicines.
Bond Pore Cargo
Drug
Loading
Content
(%)
Responsive
Stimuli
Therapy
Method
Size
(nm)
Surface
Charge
(mV)
HA
MW
(kDa)
Ref.
Amide O Dox 1.2 X Chemo 70–100 −18.8 200 [64]
Electrostatic
interaction O
TH287, MDR1
siRNA 8.91 X Chemo 184 −18.4 [72]
Amide O 6-Mercapto-purine GSH Chemo 80 −25.5–−27.9 10 [73]
Amide O CPT 0.96 X Chemo 100 −14.9 18 [75]
Amide O Dox 0.01 HAdase Chemo 232 −30 100 [65]
Amide X 5-Fluoro-uracil 15 X Chemo 138 35 [69]
GSH: Glutathione; Chemo: Chemotherapy; Dox: Doxorubicin; CPT: Camptothecin.
4.2. AuNPs
AuNPs (gold nanoparticles, gold nanorods, gold star, and gold nanocages) are used in biomedical
applications as biocompatible carriers for drug delivery [78], as contrast agents for diagnostic
imaging [79], and as PTT agents [80]. AuNPs have many useful properties, such as biocompatibility,
simple synthesis, easy surface modification, versatile conjugation with biomolecules, and tunable
optical properties, for use in cancer theranostics [78]. AuNPs with strong surface plasmon resonance
(SPR) absorption have great advantages in photothermal chemotherapy applications [81]. Their optical
properties and light absorption range are controlled by the size and shape of the AuNPs [82,83].
The AuNPs (gold nanoparticles, gold nanorods, and gold stars) are nonporous nanoparticles, but
gold nanocages are not. Therefore, drug modifications on the surface of the nanoparticle is a key
element in the field of drug delivery [84]. HA is one of the useful backbones that allows modification
of drugs and ligands to AuNP surface [85]. The carboxylic acid group of HA was functionalized to the
sulfide or catechol group through HA modification for immobilization to the AuNP surface; that is,
the functionalized HA forms an Au-sulfur bond or Au-catechol bond with AuNPs (Figure 11).
Park et al. presented HHAuNP, which consists of HA, HiLytefluorTm647 (Hilyte-647), and AuNPs
for cancer diagnosis [79]. End thiol-functionalized HA labeled with Hilyte-647 fluorescence dye (HH)
was modified to AuNPs by an Au-sulfide bond. This HH ligand lost the fluorescence due to the
nanoparticle surface energy transfer (NSET) effect between the Hilyte-647 and AuNPs. When the
modified HA was cleaved by reactive oxygen or HAdase, Hilyte-647 was released from AuNPs and
fluorescence was recovered (Figure 13B).
Yao et al. and Xu et al. showed the dual targeting AuNPs, which have extra cancer targeting ligand
(RGD, folate, anti-HER2 antibody) to enhance the cellular uptake of AuNPs [81,86,87]. Yao et al. showed
the GNR-HA-ALA/Cy7.5-HER2, which is an HA, 5-aminolevulinic acid (ALA), Cy7.5, and anti-HER2
antibody modified to the gold nanorods (GNRs) [86]. Photosensitizers, ALA and fluorescent dye
Cy7.5-NHS ester, were conjugated onto the GNR-HA via hydrazine and amide linkages, respectively.
GNR-HA-ALA/Cy7.5-HER2 could significantly enhance the cellular uptake and facilitate the imaging
(Cy7.5), PDT (ALA), and PTT (GNRs) (Figure 13A).
HA-AuNP are used in chemotherapy, PTT, PDT, and diagnostics [79]. For chemotherapy or
PDT, drugs, such as Dox [80] and curcumin [85], and photosensitizers, such as porphyrin, are
modified [88]. The stimuli-responsive release of the drugs facilitates specific cancer targeting and
diagnosis. GNR is mainly used for PTT, because the GNR absorbs NIR region light that has high
penetration ability [81,85–87]. The HA-GNR system enables PTT by generating heat without further
modifications and facilitating controlled drug release (Figure 13C) [89–91]. Characteristics of HA gold
nanomedicines are summarized in Table 4, including size and molecular length of HA.
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Figure 13. (A) Schematic representation of the processes for preparing hyaluronic acid (HA)-gold
nanorods (GNR) with responsive drug release and its application. Reproduced with permission [87]
Copyright 2018 Elsevier Ltd. (B) Schematic illustration of nanoparticle surface energy transfer (NSET)
interactions between Hilyte-647 dye labeled oligo-HA and gold nanoparticles (AuNPs). Reproduced
with permission [79] Copyright 2008 Elsevier Ltd. (C) Corresponding infrared thermal images of
GNRs-HA-Folic acid (FA)-doxorubicin (DOX) suspension at different time intervals. Reproduced
from [87] with permission. Copyright 2018 Elsevier Ltd.
Table 4. Characteristics of hyaluronic acid (HA) gold nanomedicines.
Bond Pore Cargo
Drug
Loading
Content
(%)
Responsive
Stimuli
Therapy
Method
Size
(nm)
Surface
Charge
(mV)
HA
MW
(kDa)
Ref.
Au-sulfur. X Hilyte-647 X HAdase, ROS Diagnosis 16 1790 [79]
Au-catechol O Dox X HAdase, NIR Chemo, PTT 50 −25.7 100 [80]
Au-catechol X Dox X pH, NIR Chemo, PTT 71 −11.4 8 [81]
Au-sulfur X ALA, Cy7.5 X HAdase, GSH, pH PTT, PDT 72 −13.8 8 [87]
Dox: Doxorubicin, ALA: 5-aminolevulinic acid; NIR: Near infrared; PDT: Photodynamic Therapy; PTT:
Photothermal Therapy.
4.3. MOF Nanoparticle
MOFs, composed of metal ions and organic linkers, have been studied for a variety of applications.
Recently, these materials have been scaled down to nanometer sizes. Nanoscale MOFs (NMOFs) have
been widely investigated for potential biomedical applications, such as drug delivery, imaging, PDT,
and PTT, because of their high surface area, tunable shapes, and pore size properties, and controllable
surface functionalities [92]. MOF can load a large amount of drug compared with other porous particles
because of the high surface area and pore [93]. The coordination bonding of carboxylic acid with metal
are used for HA conjugation on the MOF surface (Figure 11).
Zhao et al. showed that HA-coated Dox was loaded into zeolitic imidazolate framework-8
(Dox@ZIF-HA) for chemotherapy and MRI imaging [94]. ZIF-8, which is used as a nanocarrier, is easily
degraded in tumor pH conditions, which promotes drug release [95–97]. To prepare the Dox@ZIF-HA,
Dox@ZIF-8 was coated with polydopamine, successively chelated with Fe3+, and conjugated with
HA by a coordination bond. Furthermore, the prepared Dox@ZIF-HA is a good contrast agent for
magnetic resonance (MR) imaging because of the chelation of Fe3+ by PDA. Dox@ZIF-HA provides
targeted drug delivery, stimuli responsive drug release, and cancer imaging.
HA-MOF nanomedicine enables chemotherapy and PTT by loading various drugs, such as
Dox, indocyanine green, and cytarabine. HA-ZIF-8 is easily degraded in tumor pH conditions,
which promotes the release of the drug [94,97]. Mil-100 (Fe), which has good T2-weighted MRI
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properties, is a drug carrier for cancer imaging (Figure 14) [98]. Porphyritic MOF enables PDT without
additional compound loading, because the organic linker constituting MOF structure is used as a
photosensitizer [99]. MOF has unique characteristics for each type and can be used for various
cancer treatment applications to induce the synergistic effect with HA. Characteristics of HA MOF
nanomedicines are summarized in Table 5, including size and molecular length of HA.
Figure 14. Schematic representation of the synthesis procedure, hyaluronic acid (HA) conjugation,
Indocyanine green (ICG) loading, and multimodal imaging-guided photothermal therapy (PTT) of
MIL-100(Fe) nanoparticles (NPs). Reproduced from [98] with permission. Copyright (2017) American
Chemical Society.
Table 5. Characteristics of hyaluronic acid (HA) MOF nanomedicines
Bond Pore Cargo
Drug
Loading
Content
(%)
Responsive
Stimuli
Therapy
Method
Size
(nm)
Surface
Charge
(mV)
HA
MW
(kDa)
Ref.
Coordination O Dox pH Chemo,MRI 150 −30.2 X [94]
O Indocyaninegreen 42 NIR
PTT,
MRI, PA
imaging
106 −25.4 X [98]
O
α-Cyano-
4-hydroxy-
cinnamate
HAdase,
Light PDT 152 −13.9 X [99]
Coordination O
Cytarabine,
indocyanine
green
39.8 pH Chemo,PTT 135 10 [97]
Dox: Doxorubicin, MRI: magnetic resonance imaging; NIR: Near infrared; PDT: Photodynamic Therapy; PTT:
Photothermal Therapy.
4.4. Conclusion of HA Inorganic Nanomedicines
HA is modified on various nanoparticles with many different methods. Silica nanoparticles are
modified with HA by forming amide bonds between the amine groups on the silica surface and the
carboxylic acid groups of HA or by electrostatic interaction. HA modification of gold nanoparticles
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is performed with post-functionalization of sulfide or catechol groups on HA. In the case of MOF
nanoparticles, the metal ion in their structure coordinates with HA. Modification with HA endows
nanoparticles with cancer targeting ability, enhances the colloidal stability and biocompatibility, and
even functions as a gatekeeper to regulate the drug release. Introduction of HA onto inorganic
nanoparticles gives improved cancer therapeutic effects.
5. Conclusions
In summary, HA micelles, nanogels, and inorganic nanomedicines can effectively transfer
drugs to cancer cells through passive EPR and active targeting (receptor mediated internalization).
The carboxylic acid groups of HA enable various modifications by simple reactions. HA expands the
utilization of nanomedicines by increasing the biocompatibility, blood circulation time, cellular uptake,
and colloidal stability of inorganic nanoparticles. In particular, various drugs can be loaded into the
HA nanomedicine, facilitating chemotherapy, PTT, PDT, MRI, and fluorescence imaging.
Summing up, we have reviewed the recent progress in the field of stimuli-responsive
HA nanomedicines for cancer therapy and highlighted representative examples regarding the
stimuli-responsive temporal and spatial drug delivery and release. The potential and progress
of stimuli-responsive HA nanomedicines have been clearly shown in previous studies, yet, a correlation
between HA and protein corona formation is still not established clearly. HA prevented the formation
of protein corona on nanoparticles in one study [100], while it had no significant effect on inhibition
of protein corona formation in another study [101]. Further studies on HA’s effect on protein corona
formation need to be established. In the near future, we believe that the stimuli-responsive HA
nanomedicines will become an important component of clinical cancer therapy.
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